Australian biotech market watch 13/01/10
Wednesday, 13 January, 2010
The All Ordinaries has dipped for a second day in a row, down 35 points in afternoon trading to 4,896, eroding some of the gains made in the first week of January.
Anti-leukaemia drug company, ChemGenex (ASX:CXS), is up 1.55% to 98c, still falling just shy of the $1.00 mark.
Ramsay Health Care (ASX:RHC) has continued to make gains, up 18c to $11.63, on the back of news on Monday of an acquisition of a majority interest in French peer Groupe Proclif SAS, for $142 million.
It looks like Mesoblast's (ASX:MSB) stellar rise has plateaued, with the stock level today at $1.90, down from a brief peak above $2.00 this morning.
Biota Holdings (ASX:BTA), patent holder for anti-influenza drug, Relenza, has recovered from its dip yesterday, hovering around $2.07 after falling to below $2.00 mid-Tuesday.
Sonic Health Care (ASX:SHL) has continued its slow slide after its acquisition frenzy in late 2009, down today by 12c to $14.56.
Confidence in vaccine-maker, CSL (ASX:CSL), has recently been wavering following talk that the U.S. might cut back on swine flu vaccine orders given an oversupply of the vaccine and a relatively flaccid interest in it from the general public. CSL is down 39c to $31.50 today.
Sirtex Medical (ASX:SRX) has also shed 33c to $7.35, although there are signs of a moderate comeback this afternoon.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
